Review

Cells of the synovium in rheumatoid arthritis

Chondrocytes

Miguel Otero and Mary B Goldring

Research Division of the Hospital for Special Surgery, Weill College of Medicine of Cornell University, Caspary Research Building, 535 E. 70th Street, New York, NY 10021, USA

Corresponding author: Mary B Goldring, goldringm@hss.edu

Published: 26 October 2007
This article is online at http://arthritis-research.com/content/9/5/220
© 2007 BioMed Central Ltd

Abstract

Rheumatoid arthritis (RA) is one of the inflammatory joint diseases in a heterogeneous group of disorders that share features of destruction of the extracellular matrices of articular cartilage and bone. The underlying disturbance in immune regulation that is responsible for the localized joint pathology results in the release of inflammatory mediators in the synovial fluid and synovium that directly and indirectly influence cartilage homeostasis. Analysis of the breakdown products of the matrix components of joint cartilage in body fluids and quantitative imaging techniques have been used to assess the effects of the inflammatory joint disease on the local remodeling of joint structures. The role of the chondrocyte itself in cartilage destruction in the human rheumatoid joint has been difficult to address but has been inferred from studies in vitro and in animal models. This review covers current knowledge about the specific cellular and biochemical mechanisms that account for the disruption of the integrity of the cartilage matrix in RA.

Rheumatoid arthritis

Rheumatoid arthritis (RA) is an inflammatory joint disease that most frequently affects the anatomical components of articular and juxta-articular tissues of diarthrodial joints. The diarthrodial joints join two opposing bone surfaces that are covered by a specialized hyaline cartilage providing a low-friction, articulating interface. The synovium lines the joint cavity and is the site of production of synovial fluid, which provides the nutrition for the articular cartilage and lubricates the cartilage surfaces. In RA, the synovial lining of diarthrodial joints is the site of the initial inflammatory process [1,2]. This lesion is characterized by proliferation of the synovial lining cells, increased vascularization, and infiltration of the tissue by inflammatory cells, including lymphocytes, plasma cells, and activated macrophages [3-5]. With the growth and expansion of the synovial lining, there is eventual extension of the inflammatory tissue mass to the adjacent articular cartilage with progressive overgrowth of the articular surface and formation of the so-called pannus, which is derived from the Latin word meaning ‘cloth’ and the Greek word meaning ‘web’. At the interface between the RA synovium and articular cartilage, tongues of proliferating cells can be seen penetrating the extracellular matrix of the cartilage. Similarly, at the interface between the inflamed synovium and adjacent subchondral bone, there is evidence of local activation of bone resorption with destruction of the mineralized bone matrix, accompanied by cells expressing phenotypic features of osteoclasts, including calcitonin receptor mRNA, cathepsin K, and tartrate-resistant acid phosphatase (TRAP) [6,7]. RA synovium produces a broad spectrum of factors possessing the capacity to stimulate cartilage matrix destruction and bone erosion [3,4]. Although there is an association between inflammation and the development of joint damage, the destruction may progress in spite of attenuated inflammatory activity, and cartilage and bone erosions may develop in the absence of overt clinical signs of inflammation [8-11]. Recent evidence from human and animal studies indicates that although the specific cellular mechanisms of cartilage and bone destruction are different, TNF-α, IL-1, and additional proinflammatory cytokines and mediators can drive elements of both processes [10,12]. The recent development of assays for specific biological markers that reflect quantitative and dynamic changes in the synthetic and degradation products

AIA = antigen-induced arthritis; ADAM = a disintegrin and metalloproteinase; ADAMTS = ADAM with thrombospondin-1 domains; CD-RAP = cartilage-derived retinoic-acid-sensitive protein; CH3L1 = chitinase 3-like protein 1; CIA = collagen-induced arthritis; COMP = cartilage oligomeric matrix protein; COX = cyclooxygenase; GLUT = glucose transporter protein; HIF = hypoxia-inducible factor; IGF = insulin-like growth factor; IL = interleukin; IL-1Ra = IL-1 receptor antagonist; iNOS = inducible nitric oxide synthetase; MCP = monocyte chemoattractant protein; MIP = macrophage inflammatory protein; MMP = matrix metalloproteinase; mPGES-1 = microsomal PGE synthase-1; NF = nuclear factor; OSM = oncostatin M; PGE = prostaglandin E; PPAR = peroxisome proliferator-activated receptor; RA = rheumatoid arthritis; RANKL = receptor activator of NF-κB ligand; TGF = transforming growth factor; Th = T helper; TIMP = tissue inhibitor of metalloproteinases; TLR = Toll-like receptor; TNF = tumor necrosis factor; TRAP = tartrate-resistant acid phosphatase; VCAM = vascular cell adhesion molecule; VEGF = vascular endothelial growth factor.
of cartilage and bone matrix components has offered the possibility of identifying patients at risk for rapid joint damage and also the possibility of early monitoring of the efficacy of disease-modifying anti-rheumatic therapies [13-15]. This review will focus on the unique ways in which the chondrocyte responds to the inflammatory milieu and contributes to the disease process in the cartilage.

The chondrocyte in adult articular cartilage

Adult human articular cartilage, which covers the articulating surfaces of long bones, is populated exclusively by chondrocytes that are somewhat unique to this tissue. The collagen network of the interterritorial cartilage matrix is composed of types II, IX, and XI collagens, which provide tensile strength and promote the retention of proteoglycans. Type XI collagen is part of the type II collagen fibril, and type IX integrates with the surface of the fibril with the non-collagen domain projecting outward, permitting association with other matrix components. The other major component, the large aggregating proteoglycan aggrecan, which is attached to hyaluronic acid polymers via link protein, bestows compressive resistance. A large number of other non-collagen molecules are present in the interterritorial matrix; these molecules include several small proteoglycans such as biglycan, decorin, fibromodulin, the matrilins, and cartilage oligomeric matrix protein (COMP). The chondrocytes are surrounded by a pericellular matrix composed of type VI collagen microfibrils that interact with hyaluronic acid, biglycan, and decorin and maintain chondrocyte attachment, but little or no fibrillar collagen. Under physiological conditions, the chondrocytes maintain a stable equilibrium between the synthesis and the degradation of matrix components, with a half-life of more than 100 years for type II collagen [16] and a half-life for aggrecan core protein in the range 3 to 24 years [17]. The glycosaminoglycan components of aggrecan and other cartilage matrix constituents also are synthesized by chondrocytes under conditions of low turnover, and the matrix turnover may be more rapid in the immediate pericellular zones.

Under normal conditions, chondrocyte proliferation is limited, and penetration of other cell types from the joint space or subchondral bone is restricted. In the absence of a vascular supply, the chondrocyte must rely on diffusion from the articular surface or subchondral bone for the exchange of nutrients and metabolites. Glucose serves both as the major energy source for the chondrocytes and as an essential precursor for glycosaminoglycan synthesis. Facilitated glucose transport in chondrocytes is mediated by several distinct glucose transporter proteins (GLUTs) that are either expressed constitutively (GLUT3 and GLUT8) or inducible by cytokines (GLUT1 and GLUT6) [18,19]. Chondrocytes do not contain abundant mitochondria, but they maintain active membrane transport systems for exchange of cations, including Na+, K+, Ca2+, and H+, whose intracellular concentrations fluctuate with charge, biomechanical forces, and alterations in the composition of the cartilage matrix [20]. Furthermore, chondrocyte metabolism operates at low oxygen tension, ranging from 10% at the surface to less than 1% in the deep zones of the cartilage. Chondrocytes adapt to low oxygen tensions by upregulating hypoxia-inducible factor (HIF)-1α, which can stimulate the expression of GLUTs [19] and angiogenic factors such as vascular endothelial growth factor (VEGF) [21,22], as well as ascorbate transport [23] and several genes associated with cartilage anabolism and chondrocyte differentiation, including Sox9 and type II collagen [24]. By modulating the intracellular expression of survival factors such as HIF-1α, chondrocytes have a high capacity to survive in the avascular cartilage matrix and to respond to environmental changes.

Joint inflammation and cartilage remodeling in RA

Cartilage destruction in RA occurs primarily in areas contiguous with the proliferating synovial pannus [25,26]. In the cartilage–pannus junction, there is evidence of attachment of both fibroblast-like and macrophage-like synovial cell types, which can release proteinases capable of digesting the cartilage matrix components [27]. A distinctive fibroblast-like cell type, the so-called ‘pannocyte’, present in RA synovium exhibits anchorage-independent growth and can invade cartilage in the absence of an inflammatory environment [2]. Nevertheless, there is evidence of loss of proteoglycan throughout the cartilage matrix, particularly in the superficial zone in contact with the synovial fluid at sites not directly associated with the pannus [28,29]. This has been attributed to the release of inflammatory mediators and degradative enzymes released by polymorphonuclear leukocytes and other inflammatory cells in the synovial fluid. In early RA, however, the loss of proteoglycan occurs throughout the cartilage matrix, and selective damage to type II collagen fibrils can be observed in middle and deep zones [30,31], suggesting that the chondrocyte may also participate in degrading its own matrix by releasing autocrine–paracrine factors.

Of the matrix metalloproteinases (MMPs) involved in the degradation of cartilage collagens and proteoglycans in RA, the MMPs of the collagenase and stromelysin families have been given greatest attention because they specifically degrade native collagens and proteoglycans. Active stromelysin also serves as an activator of latent collagenases [32]. MMPs are localized at sites of degradation in cartilage derived from patients with RA [33]. Collagenases 1, 2, and 3 (MMP-1, MMP-8, and MMP-13, respectively), gelatinases (MMP-2 and MMP-9), stromelysin-1 (MMP-3), and membrane type I MMP (MT1-MMP; MMP-14) are present in active RA synovium [34,35]. Although elevated levels of MMPs in the synovial fluid probably originate from the synovium, intrinsic chondrocyte-derived chondrolytic activity is present at the cartilage–pannus junction as well as in deeper zones of cartilage matrix in some RA specimens [36]. For example,
MMP-1 does not derive from the RA synovial pannus but is produced by chondrocytes [37]. MMP-10, similarly to MMP-3, activates procollagenases and is produced by both the synovium and chondrocytes in response to inflammatory cytokines [38]. In contrast, MMP-14, produced principally by the synovial tissue, is important for synovial invasiveness, and inhibition of the expression of this membrane proteinase by antisense mRNA has been shown to reduce cartilage destruction [39].

Other MMPs, including MMP-16 and MMP-28 [40,41], and a large number of members of the represyn-related proteinases of the ADAM (a disintegrin and metalloproteinase) family, including ADAM-17/TACE (TNF-α converting enzyme) [42], are expressed in cartilage, but their roles in cartilage damage in RA have yet to be defined [32,43,44]. Although several of the MMPs, including MMP-3, MMP-8, and MMP-14, are capable of degrading proteoglycans, ADAMTS (ADAM with thrombospondin-1 domains)-4 and ADAMTS-5 are now regarded as the principal mediators of aggrecan degradation [45,46]. ADAMTS-4 is expressed constitutively, whereas ADAMTS-5 is more prominently regulated by inflammatory cytokines. However, the activities of MMPs and aggrecanases are complementary [47]. Of the aggrecanases, so far only aggrecanase-2, ADAMTS5, seems to be associated with increased susceptibility to osteoarthritis, as shown in Adamts5-deficient mice [48,49]. Tissue inhibitor of metalloproteinases (TIMP)-3, but not TIMP-1, TIMP-2, or TIMP-4, is a potent inhibitor of ADAMTS-4 and ADAMTS-5 in vitro [50]. That capacity of transforming growth factor (TGF)-β to increase TIMP gene expression may partly account for its protective effects against cartilage breakdown mediated by MMP and by ADAMTS [51,52].

Other proteinases, including the urokinase-type plasminogen activator and the cathepsins B, L, and D, which degrade various cartilage matrix components and may be produced by the chondrocytes themselves, also contribute to breakdown of the cartilage matrix [53,54]. Cathepsin K is expressed in synovial fibroblasts on the cartilage surface at the cartilage–pannus junction and is upregulated by inflammatory cytokines [55]. Among the known cathepsins, cathepsin K is the only proteinase that is capable of hydrolyzing types I and II collagens at multiple sites within the triple-helical regions, and its requirement for acidic pH may be provided by the microenvironment between the synovial pannus and the cartilage [56].

Degraded cartilage matrix components are to be considered both diagnostic markers of cartilage damage and potential autoantigens in the induction and maintenance of RA synovial inflammation [13,15]. Molecules originating from the articular cartilage, including aggrecan fragments, which contain chondroitin sulfate and keratan sulfate, type II collagen fragments, collagen pyridinoline cross-links, and COMP, are usually released as degradation products as a result of catabolic processes. Specific antibodies that detect either synthetic or cleavage epitopes have been developed to study biological markers of cartilage metabolism in RA body fluids (reviewed in [14]). These include the C2C antibody (previously known as Col2-3/4C_long mono), which has been used to detect cleavage of the triple helix of type II collagen in experimental models of RA and in RA cartilage [57]. Similarly, the degradation of aggrecan in cartilage has been characterized by using antibodies 846, 3B3 and 7D4 (which detect chondroitin sulfate neoepitopes), 5D4 (which detects keratan sulfate epitopes), and the VIDIPEN and NITEGE antibodies (which recognize aggrecanase and MMP cleavage sites, respectively), within the interglobular G1 domain of aggrecan [45,54].

Several studies have shown that COMP levels reflect processes in cartilage that are distinct from inflammatory aspects of the disease and serve as a general indicator of cartilage turnover [58]. YKL-40/HC-gp39, also known as chitinase 3-like protein 1 (CH3L1), is a specific histological marker in inflamed RA synovium that forms immune complexes with HLA-DR4 [59]. The immune response to YKL-40, which is biased toward the regulatory, suppressor T-cell phenotype in healthy individuals, is shifted from an anti-inflammatory to a proinflammatory phenotype in patients with RA [60]. In cartilage, CH3L1 is induced by inflammatory cytokines. It inhibits cytokine-induced cellular responses and may function as a feedback regulator [61,62]. A related member of the chitinase family, YKL-39, may be a more specific serum marker as a cartilage-derived autoantigen [63,64]. Another novel molecule is the cartilage-derived retinoic-acid-sensitive protein (CD-RAP), also known as melanoma inhibitory activity, which is found at high levels in synovial fluids from patients with mild RA and decreases with disease progression [65].

**Mediators of cartilage degradation in RA**

There is evidence that the chondrocytes may not only participate in the destruction of the cartilage matrix by responding to the proinflammatory cytokines released from the synovium but may themselves also be the source of pro-inflammatory cytokines that, by means of autocrine or paracrine mechanisms, increase tissue catabolism and suppress anabolic repair processes. The resultant disequilibrium in remodeling probably contributes to the rapid loss of cartilage matrix components characteristic of the RA joint lesion. Our understanding of basic cellular mechanisms regulating chondrocyte responses to inflammatory cytokines has been inferred from numerous studies *in vitro* with cultures of cartilage fragments or isolated chondrocytes and is supported by studies in experimental models of inflammatory arthritis such as collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA) in mice. Less information has been derived from direct analysis of cartilage or chondrocytes obtained from patients with RA in whom cartilage damage is extensive.
Inflammatory cytokines

Alterations in products of cartilage matrix turnover and levels of matrix-degrading proteinases and inhibitors described above are accompanied by changes in the levels of various cytokines in the rheumatoid synovial fluids (Fig. 1). Numerous studies in vitro and in vivo indicate that IL-1 and TNF-α are the predominant catabolic cytokines involved in the destruction of the articular cartilage in RA [10,66,67]. The first recognition of IL-1 as a regulator of chondrocyte function stems largely from work in culture models showing that activities derived from synovium or monocyte-macrophages induce the production of cartilage-degrading proteinases (reviewed in [66]). IL-1 has the capacity to stimulate the production of most, if not all, of the proteinases involved in cartilage destruction and it colocalizes with TNF-α, MMP-1, MMP-3, MMP-8, and MMP-13, and type II collagen cleavage epitopes in regions of matrix depletion in RA cartilage [34,57]. Originally known as cachectin, TNF-α produces many effects on chondrocytes in vitro that are similar to those of IL-1, including stimulation of the production of matrix-degrading proteinases and suppression of cartilage matrix synthesis. IL-1 is 100-fold to 1,000-fold more potent on a molar basis than TNF-α, but strong synergistic effects occur at low concentrations of the two cytokines together [10].

The concept that TNF-α drives acute inflammation, whereas IL-1 has a pivotal role in sustaining both inflammation and cartilage erosion, has been derived from work in transgenic or knockout mouse models [67]. For example, the spontaneous development of a chronic destructive arthritis in mice deficient in IL-1 receptor antagonist (IL-1Ra) established the importance of IL-1 in arthritis [68]. In the original study...
showing that transgenic or dysregulated overexpression of the TNF-α in causes polyarthritis in mice, chondrocytes were found to express the human transgenic [69]. When backcrossed with arthritis-susceptible DBA/1 mice, a more severe, erosive arthritis developed during successive generations [70]. Because few chondrocytes remained in older mice with advanced arthritis and the extracellular matrix of the cartilage was relatively preserved, it was proposed that the chondrocytes may die early in the life of the mice by TNF-α-driven apoptosis before significant proteoglycan degradation can occur [70]. The higher potency of IL-1 compared with TNF-α in driving cartilage erosion is supported by studies showing that blockade of IL-1 is more effective than TNF-α neutralization in CIA mice [71] and that IL-1 is a secondary mediator in TNF-α transgenic mice [72]. Later studies in the human RA/SCID (severe combined immunodeficiency) mouse chimera indicated that TNF-α is a key molecule in the inflammatory changes that occur in the rheumatoid synovium, whereas cartilage damage occurs independently of this cytokine [73]. Despite these findings in animal models, anti-TNF therapy in patients with RA has been more successful in preventing cartilage and bone destruction. This could be related to the pharmacokinetic properties of IL-1Ra. It has been suggested that alternative approaches for targeting IL-1, including the use of soluble receptors and neutralizing antibodies, need to be tested [67,74]. Supporting the concept that IL-1 drives cartilage destruction are the findings of a recent study by Schett’s group in which crossing the arthritic human TNF transgenic (hTNFtg) mice with mice deficient in IL-1α and IL-1β protected against cartilage erosion without affecting synovial inflammation [75].

Cytokine networks

IL-1 and TNF-α can also induce chondrocytes to produce several other proinflammatory cytokines, including IL-6, leukemia inhibitory factor (LIF), IL-17, and IL-18, and chemokines [76,77] (Fig. 1). IL-6 seems to perform a dual function by increasing products that downregulate inflammation such as IL-1Ra, soluble TNF receptor (sTNFR), and TIMPs, while also enhancing immune cell function and inflammation [41,78]. The inhibition of proteoglycan synthesis and other chondrocyte responses in vitro require the soluble IL-6 receptor α (sIL-6Rα), which permits the synergistic stimulation of MMP expression by IL-1 and IL-6 [79]. IL-6 blockade is under current investigation in animal models and clinical trials [80,81]. The use of the IL-6 gene promoter as an inducible adenoviral gene delivery system proposed for the local treatment of arthritis would presumably target cartilage destruction as well as inflammation [82]. Other members of the IL-6 family that act through receptors that heterodimerize with gp130 may also modulate chondrocyte function. IL-11 shares several actions of IL-6, including the stimulation of TIMP production without affecting MMP production [79] and may actually inhibit cartilage destruction [83]. Leukemia inhibitory factor (LIF), similarly to the other chondrocyte-derived autocrine factors described above, may participate in a positive feedback loop by increasing the production of IL-6 by chondrocytes. Oncostatin M (OSM), which is a product of macrophages and activated T cells, can act alone or synergistically with IL-1 to stimulate the production of MMPs and aggrecanases by chondrocytes [38,79,84]. Direct evidence supporting a role for OSM in contributing to cartilage loss in inflammatory arthritis is provided by studies in animal models [85,86].

IL-17A, one of at least six family members, is primarily a product of T helper type 17 (Th17) cells, a newly described subset of T cells, which is a potent inducer of catabolic responses in chondrocytes by itself or in synergy with other cytokines [87,88]. IL-17 can drive T-cell-dependent erosive arthritis in the TNF-deficient and IL-1Ra knockout mice, and treatment of mice with CIA or AIA with neutralizing IL-17 antibody effectively inhibits cartilage destruction in those models of RA [89-92].

The IL-1R/Toll-like receptor (TLR) superfamily of receptors has a key role in innate immunity and inflammation. Studies in arthritis induced with streptococcal cell wall showed that joint inflammation and cartilage proteoglycan loss is predominantly dependent on TLR-2 signaling [93]. Human articular chondrocytes can express TLR-1, TLR-2, and TLR-4, and activation of TLR-2 by IL-1, TNF-α, peptidoglycans, lipopolysaccharide, or fibronectin fragments increases the production of MMPs, nitric oxide (NO), prostaglandin E (PGE), and VEGF [94-96]. In arthritis mediated by immune complex, TLR-4 regulates early-onset inflammation and cartilage destruction by IL-10-mediated upregulation of Fcγ receptor expression and enhanced production of cytokines [97]. Because the IL-18 receptor shares homology with IL-1Rα and has a TLR signaling domain, therapeutic strategies similar to those for targeting IL-1 signaling have been explored [78,98]. In animal models, IL-18, by means of TLR-2, promotes joint inflammation in a partly TNF-α-dependent manner and induces IL-1-driven cartilage destruction [99]. IL-18 has effects similar to IL-1 in human chondrocytes, and stimulates chondrocyte apoptosis, although studies do not suggest a pivotal role in cartilage destruction in RA [100-102]. Of the other members of the IL-1 family recently identified by DNA database searches, IL-1F8 seems to be capable of stimulating the production of IL-6, IL-8, and NO by human chondrocytes, but at 100-fold to 1,000-fold higher concentrations than that of IL-1 [103]. IL-32, a recently discovered cytokine that induces TNF-α, IL-1β, IL-6, and chemokines and is expressed in the synovia of patients with RA, contributes to TNF-α-dependent inflammation and a loss of cartilage proteoglycan [104].

IL-4, IL-10, and IL-13 are generally classified as inhibitory or modulatory cytokines because they are able to inhibit many of the cartilage catabolic processes induced by proinflammatory cytokines [105]. Their therapeutic application has been proposed to restore the cytokine balance in RA [106,107].
The efficacy of IL-4, IL-10, and IL-13 in retarding cartilage damage may be related, in part, to their stimulatory effects on IL-1Ra production [108,109]. Despite the capacity of IL-4 to inhibit the effects of proinflammatory cytokines on chondrocyte function [110,111], differential effects have been observed in mice, depending on the model used [112,113]. Gene transfer of IL-10 in combination with IL-1Ra inhibits cartilage destruction by a mechanism involving activin, a TGF-β family member [114]. IL-10 is part of the response induced by immunomodulatory neuropeptides that have recently been shown to inhibit inflammation and cartilage and bone destruction by downregulating the Th1-driven immune response and upregulating IL-10/TGF-β-producing regulatory T (Treg) lymphocytes [115]. IL-13 decreases the breakdown of collagen and proteoglycans by inhibiting IL-1- and OSM-induced MMP-3 and MMP-13 expression [116]. Local gene transfer of IL-13 inhibits chondrocyte death and MMP-mediated cartilage degradation despite enhanced inflammation in the immune-complex arthritis model [117].

**Mediators and mechanisms in the responses of chondrocytes to inflammatory cytokines**

In addition to inducing the synthesis of MMPs and other proteinases by chondrocytes, IL-1 and TNF-α upregulate the production of NO by means of inducible nitric oxide synthetase (iNOS, or NOS2), and that of PGE₂ by stimulating the expression or activities of cyclooxygenase (COX)-2, microsomal PGE synthase-1 (mPGES-1), and soluble phospholipase A₂ (sPLA₂). Although PGE₂ and NO have been well characterized as proinflammatory mediators, there is evidence of crosstalk between them in the regulation of chondrocyte function (reviewed in [118]). COX-2 is also involved in the chondrocyte response to high shear stress, associated with decreased antioxidant capacity and increased apoptosis [119]. In the production of prosta-glandins, mPGES-1, which is induced by IL-1 in chondrocytes, is a major player [120,121]. In addition to opposing the induction of COX-2, iNOS, and MMPs and the suppression of aggrecan synthesis by IL-1, activators of the peroxisome proliferator-activated receptor γ (PPAR-γ), including the endogenous ligand 15-deoxy-A₁₂,₁₄-prostaglandin J₂ (PGJ₂), inhibit the IL-1-induced expression of mPGES-1 [122,123]. Recent evidence indicates that PPAR-α agonists may protect chondrocytes against IL-1-induced responses by increasing the expression of IL-1Ra [124].

Adipokines, which were originally identified as products of adipocytes, have recently been shown to have roles in cartilage metabolism [125]. White adipose tissue has been proposed as a major source of both proinflammatory and anti-inflammatory cytokines, including IL-1Ra and IL-10 [126]. Leptin expression is enhanced during acute inflammation, correlating negatively with inflammatory markers in RA sera [127], and has been proposed to serve as a link between the neuroendocrine and immune systems [128]. The elevated expression of leptin in OA cartilage and in osteophytes, and its capacity to stimulate insulin-like growth factor (IGF)-1 and TGF-β1 synthesis, suggest a role for this adipokine in anabolic responses of chondrocytes [129]. Leptin synergizes with IL-1 or interferon-γ to increase NO production in chondrocytes [130], and leptin deficiency attenuates inflammatory processes in experimental arthritis [131]. It has been proposed that the dysregulated balance between leptin and other adipokines, such as adiponectin, promotes destructive inflammatory processes [132].

Several additional mediators that affect chondrocyte metabolism have been described. The IL-1-induced SOCS3 (suppressor of cytokine signaling 3) acts as a negative feedback regulator during desensitization toward IGF-1 in the absence of NO by inhibiting the phosphorylation of insulin receptor substrate (IRS)-1 [133]. Recent evidence indicates that RAGE, the receptor for advanced glycation end products (AGEs), interacts preferentially with S100A4, a member of the S100 family of calcium-binding proteins, in chondrocytes and stimulates MMP-13 production through the phosphorylation of Pyk2, mitogen-activated protein kinases, and NF-κB [134]. The fibroblast activation protein α (FAP-α), a membrane serine proteinase, which colocalizes in synovium with MMP-1 and MMP-13 and is induced by IL-1 and OSM in chondrocytes, may have a role in collagen degradation [135,136]. Many of these proteins may be activated during the chondrocyte response to abnormal stimuli and may serve as endogenous mediators of cellular responses to stress and inflammation.

**Signaling mechanisms, gene transcription, and genome analyses**

Signal transduction molecules and transcription factors activated by inflammatory mediators in chondrocytes and synovial cells have been studied to identify potential therapeutic targets. For example, NF-κB is a ‘master switch’ of the inflammatory cascade [137], and the signaling intermediates in the p38 and JNK pathways have also been targeted for future therapeutic development [138]. In addition to NF-κB, members of the CCAAT-enhancer-binding protein (C/EBP), Ets, and activator protein (AP)-1 families are important for the regulation of gene expression by IL-1 and TNF-α [43,139-142] and have been localized in rheumatoid tissues [143,144]. The JAK/Stat3 signaling pathway is important for signaling by gp130 cytokines [145]. Cytokine-induced transcription factors also suppress the expression of several genes associated with the differentiated chondrocyte phenotype, including type II collagen (COL2A1), aggrecan, and CD-RAP [146-148]. Chondrocyte-specific transcription factors, including Sox9 (which regulates cartilage formation during development [139]), have not been studied in the context of cartilage metabolism in RA. Genomic and proteomic analyses that have been performed in cytokine-treated chondrocytes, in cartilage from patients with osteoarthritis, and in rheumatoid synovium have provided some insights into novel mechanisms that might govern chondrocyte responses in RA [149-154]. So far, more than
1,000 differentially expressed transcripts have been identified in cartilage derived from patients with arthritis [155].

**Chemokines**

The role of chemokines in RA synovium, where they are involved in neutrophil activation, chemotaxis, and angiogenesis, is well established, but their potential contribution to cartilage metabolism has been recognized only recently [156-159]. IL-8, probably the most potent and abundant chemotactic agent in RA synovial fluids, and other chemokines, such as monocyte chemoattractant protein (MCP)-1 and RANTES, are produced primarily by the synovium and serve as indicators of synovitis. Chondrocytes, when activated by IL-1 and TNF-α, express several chemokines, including IL-8, MCP-1, and MCP-4, macrophage inflammatory protein (MIP)-1α, MIP-1β, RANTES, and GROα, as well as receptors that enable responses to some of these chemokines, and may feedback regulate synovial cell responses [160,161]. High levels of stromal cell-derived factor 1 (SDF-1) are detected in RA synovial fluids, and its receptor, CXCR4, is expressed by chondrocytes but not synovial fibroblasts, suggesting a direct influence of this chemokine on cartilage damage [162]. Microarray studies have elucidated several chemokines that are inducible in chondrocytes by fibronectin fragments and cytokines [154].

**Adhesion molecules and angiogenesis**

In addition to the requirement of chemokines for the recruitment of T lymphocytes and other inflammatory cells to the subsynovial lining, adhesion receptors must be available on synovial blood vessels for binding the circulating leukocytes and other cell types with which they interact in the inflamed tissue, including macrophages, dendritic cells, and fibroblasts. The principal families of adhesion molecules involved are the selectins, the integrins, the cadherins, and variants of the immunoglobulin supergene family. Although these molecules are common to different inflammatory sites, many of the prominent adhesion proteins expressed in the inflamed rheumatoid synovium are also expressed in cartilage. For example, vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1, which are members of the immunoglobulin family, are expressed by human articular chondrocytes as well as synovial and endothelial cells, although their function on chondrocytes may not be significant unless damage to the matrix permits cell–cell interactions [163]. VCAM-1, as well as VEGF, fibroblast growth factor (FGF), and TNF-α, contributes to angiogenesis during synovitis and to the activation of chondrocytes during cartilage degradation [164,165]. VEGF expression is upregulated by inflammatory cytokines in both chondrocytes and synovial cells and by hypoxia [166,167], and Vegfb knockout mice are protected against synovial angiogenesis in the CIA and AIA models [168].

Several members of the integrin family are expressed by chondrocytes. The α1β1 and α5β1 integrins function as receptors for fragments of collagen and fibronectin, respectively. The stimulation of α5β1 integrin by integrin-activating antibodies or fibronectin fragments results in increased MMP production and requires reactive oxygen species [169]. In contrast, the discoidin domain receptor-2 specifically increases MMP-13 production by recognizing intact type II collagen fibrils that have been denuded by proteoglycans, as occurs in osteoarthritis [170,171], but its role in RA has not been determined. Specific roles for the hyaluronan receptor, CD44, in cell–matrix interactions in cartilage have also been identified [172]. CD44 expression is upregulated on chondrocytes in articular cartilage and synoviocytes from patients with RA [173,174]. Hyaluronan binding to CD44 increases MMP-13 and NO production by chondrocytes [175]. Furthermore, induction of MMP-specific cleavage of type II collagen and NO production by the heparin-binding fragment of fibronectin is mediated by CD44 [176].

Cadherins are adhesion molecules that mediate cell–cell adhesion by binding a cadherin of the same cell type on an adjacent cell. The recent identification of cadherin-11 as a key adhesion molecule, which regulates the formation of the synovial lining during development and the synoviocyte function postnatally, has provided the opportunity to examine its role in inflammatory joint disease [177]. Cadherin-11 deficiency, or treatment with cadherin-11 antibody or a cadherin-11 fusion protein, decreased synovial inflammation and decreased cartilage erosion in an animal model of arthritis. Furthermore, cadherin-11 facilitated synoviocyte invasion into cartilage-like extracellular matrix in an in vitro model, suggesting that this molecule could serve as a specific target for therapy against cartilage destruction in inflammatory arthritis [178].

**Bone-related factors**

The potent induction by IL-17 of receptor activator of NF-κB ligand (RANKL), which is produced by synoviocytes and T cells in RA synovium [179] and mediates osteoclast differentiation and activity, may partly account for the capacity of IL-17 to induce bone destruction in an IL-1-independent manner and bypass the requirement for TNF in the development of inflammatory arthritis [88]. Both RANKL and its receptor RANK, a member of the TNF receptor family, are expressed in adult articular chondrocytes [180], but a direct action in cartilage has not yet been identified. Although RANKL deficiency blocks bone destruction without direct effects on cartilage destruction in inflammatory models, it is possible that indirect cartilage-protective effects may occur through interference with the degradation of subchondral bone [179,181,182].

Wnt signaling, through the canonical β-catenin pathway and activation of T-cell factor (TCF)/Lef transcription factors, functions in a cell-autonomous manner to induce osteoblast differentiation and suppress chondrocyte differentiation in early osteo-chondroprogenitors [183]. During chondro-
genesis, Wnt/β-catenin acts at two stages, at low levels to promote chondroprogenitor differentiation and later at high levels to promote chondrocyte hypertrophic differentiation and subsequent endochondral ossification [183,184]. Because ectopic Wnt/β-catenin signaling leads to enhanced ossification and the suppression of cartilage formation during skeletal development, the disruption of Wnt signaling in adult cartilage would be expected to have pathological consequences. For example, activation of β-catenin in mature cartilage cells stimulates hypertrophy, matrix mineralization, and expression of VEGF, ADAMTS5, MMP-13, and several other MMPs [184]. A recent study showed limited expression of β-catenin in joint tissues of patients with RA, but high expression of the inhibitor of Wnt/β-catenin signaling, DKK-1, in the inflamed synovium, especially in the synoviocytes and synovial microvessels, and in cartilage adjacent to inflammatory tissue [185]. This study also showed expression of DKK-1 in a TNF-α-dependent manner in TNF transgenic mice and blockade of RANKL-dependent bone resorption by the administration of DKK-1 antibody, as a result of upregulation of the RANKL inhibitor osteoprotegerin [185] (reviewed in [186]).

Conclusion

Significant advances have been made in recent years that have contributed to our understanding of the cellular interactions in the RA joint involving macrophages, T and B lymphocytes, and synovial fibroblasts. Laboratory investigations in vitro and in vivo have resulted in new findings about the role of the chondrocyte in remodeling the cartilage matrix in the RA joint. Although the mediators involved in immunomodulation and synovial cell function, including cytokines, chemokines, and adhesion molecules, have primary roles in the inflammatory and catabolic processes in the joint, they may also promote cartilage damage, directly or indirectly. Despite the clinical success of anti-TNF therapy for RA, there is still a need for therapeutic strategies that prevent the extensive cartilage and bone loss. Recent work that has identified novel molecules and mechanisms, as well as providing new understanding of the contributions of known mediators, offers the possibility of developing new therapies for targeting cartilage destruction in inflammatory joint disease.

Competing interests

The authors declare that they have no competing interests.

References

1. Tak PP, Bresnihan B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000, 43:2619-2633.
2. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
3. Meyer LH, Franssen L, Pap T: The role of mesenchymal cells in the pathophysiology of inflammatory arthritis. Best Pract Res Clin Rheumatol 2008, 20:969-981.
4. Knedla A, Neumann E, Muller-Ladner U: Developments in the synovial biology field. Arthritis Res Ther 2007, 9:209.
5. Szekanecz Z, Koch AE: Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007, 19:289-295.
6. Gravallese EM, Harada Y, Wang J-T, Gorn A, Thornhill T, Goldring SR: Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951.
7. PHELPS AR, Walsh NC, Manning C, Goldring SR, Gravallese EM: RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:1068-1076.
8. Mulherin D, Fitzgerald O, Bresnihan B: Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996, 35:1263-1268.
9. Kimura J, Byron M, Watt I: The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis. Rheumatology (Oxford) 2001, 40:297-301.
10. van den Berg WB, van Riel PL: Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality? Arthritis Rheum 2005, 52:995-999.
11. Graudal N: The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol Suppl 2004, 1-38.
12. van Lent PL, Grevers L, Lubberts E, de Vries TJ, Nabbe KC, Verbeek S, Oppers B, Sloetjes A, Blom AB, van den Berg WB: Fcy receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum 2006, 54:386-397.
13. Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP: Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Rheum 2008, 6:R31.
14. Goldring SR, Goldring MB: Rheumatoid arthritis and other inflammatory joint pathologies. In Dynamics of Bone and Cartilage Metabolism. 2nd edition. Edited by Seibel MJ, Robins SP, Rieckjian JP, San Diego: Academic Press; 2006:843-869.
15. Charni-Ben Tabassi N, Garnero P: Monitoring cartilage turnover. Curr Rheumatol Rep 2007, 9:16-24.
16. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, Bijlsma JW, Lafeber FP, Baynes JW, TeKoppele JM: Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000, 275:39027-39031.
17. Maroudas A, Bayli SS, Uchitel-Kaushansky N, Schneiderman R, Gilav E: Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. Arch Biochem Biophys 1998, 350:71-77.
18. Shikhaman AR, Brinon DC, Lotz MK: Distinct pathways regulate facilitated glucose transport in human articular chondrocytes during anabolic and catabolic responses. Am J Physiol Endocrinol Metab 2004, 286:E880-E885.
19. Mobasheri A, Richardson S, Mobasher R, Shakhbaei M, Hoyland JA: Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol Histopathol 2005, 20:1327-1338.
20. Wilkins RJ, Browning JA, Ellory JC: Surviving in a matrix: membrane transport in articular chondrocytes. J Membr Biol 2000, 177:95-108.
21. Pufe T, Kurz B, Petersen W, Varoga D, Mintlein R, Kulow S, Lemke A, Tillmann B: The influence of biomechanical parame-
ners on the expression of VEGF and endostatin in the bone and joint system. Ann Anat 2005, 187:461-472.

22. Lin C, McGough R, Asaw B, Block J, Terek R: Hypoxia induces HIF-1α and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 2004, 22:1175-1181.

23. McNulty AL, Stabler TV, Vail TP, McDaniel GE, Kraus VB: Dehydroascorbate transport in human chondrocytes is regulated by hypoxia and is a physiologically relevant source of ascorbate in the joint. Arthritis Rheum 2005, 52:2676-2685.

24. Robins JC, Akeno N, Mukherjee A, Dalal RR, Aronow BJ, Kooiman P, Clemens T: Hypoxia induces chondrocyte-specific gene expression in mesenchymal cells in association with transcriptional activation of Sox9. Bone 2005, 37:313-320.

25. Kobayashi I, Ziff M: Electron microscopic studies of the cartilage–pannus junction in rheumatoid arthritis. Arthritis Rheum 1975, 18:475-483.

26. Woolley DE, Crossley MJ, Evanson JM: Collagenase at sites of osteolysis in the rheumatoid joint. Arthritis Rheum 1977, 20:1231-1239.

27. Edwards JCW: Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis. Arthritis Res 2000, 2:344-347.

28. Kimura H, Tateishi HJ, Ziff M: Surface ultrastructure of rheumatoid articular cartilage. Arthritis Rheum 1977, 20:1085-1098.

29. Dodge GR, Poole AR: Immunohistochemical detection and immunochromatographic analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989, 83:647-661.

30. Mitchell NS, Shepard N: Changes in proteoglycan and collagen in cartilage in rheumatoid arthritis. J Bone Joint Surg 1978, 60A:349-354.

31. Dodge GR, Pidoux I, Poole AR: The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscopic study. Matrix 1991, 11:330-338.

32. Murphy G, Lee MH: What are the roles of metalloproteinases in cartilage: An osteo-bone damage? Ann Rheum Dis 2005, 64 (Suppl 4)v44-v47.

33. Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL: Immunocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1998, 57:240-32.

34. Tetlow LC, Woolley DE: Comparative immunocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synovio- lastellate cells in vitro. J Rheumatol 1998, 25:3764-3770.

35. Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, Bresnihan B: Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001, 44:1744-1753.

36. Woolley DE, Tetlow LC: Observations on the microenvironmental nature of cartilage degradation in rheumatoid arthritis. Ann Rheum Dis 1997, 56:151-161.

37. Ainola MM, Mandelin JA, Liestompo MP, Li TF, Hukkanen MV, et al.: Metalloproteinase 10 promotion of collagenolysis via procol-lagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum 2006, 54:3244-3253.

38. Rutkowskaite E, Volkmer D, Shigeyama Y, Schedel J, Pap G, Muller-Ladner U, Meinecke I, Alexander D, Gay RE, Drynda S, et al.: Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2005, 52:2010-2014.

39. Keverkian L, Young DA, Darrah C, Donnell ST, Shepatone L, Porter SR, Brockbank SM, Edwards DR, Parker AE, Clark IM: Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004, 50:131-141.

40. Cawston TE, Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2005, 20:993-1002.

41. Patel IR, Attur MG, Patel RN, Stuchin SA, Abagyan RA, Abramson SB, Amin AR: TNF-α convertase enzyme from human arthritis-affect ed cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-α. J Immunol 1998, 160:4570-4579.

42. Burrage PS, Huntington JT, Sporn MB, Brinckerhoff CE: Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand. Arthritis Rheum 2007, 56: 245-257.

43. Overall CM, Blobel CP: In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 2007, 8:245-257.

44. Amer EC: Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol 2007, 7:229-232.

45. Plassa A, Osborn B, Yoshihara Y, Bai Y, Bloom T, Nelson F, Mikecz K, Sandy JD: Aggrecananalysis in human osteoarthristis: confocal localization and biochemical characterization of ADAMTS5–hyaluronan complexes in articular cartilages. Osteoarthritis Cartilage 2007, 15:780-787.

46. Sandy JD: A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecananalysis. Osteoarthritis Cartilage 2006, 14:95-100.

47. Shahin T, Rogerson F, East CJ, Golub SB, Lawer KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, et al.: ADAMTS5 is the major aggrecanase in mouse cartilage in vitro and in vivo. Nature 2005, 434:648-652.

48. Glasson SS, Askew F, Sheppard P, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki Y, Yang Z, et al.: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.

49. Kashwagi M, Tortorella N, Nagase H, Brew K: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAMTS4) and aggrecanase 2 (ADAMTS-5). J Biol Chem 2001, 276:12501-12504.

50. Hui W, Cawston T, Rowan AD: Transforming growth factor β1 and insulin-like growth factor 1 block collagen degradation induced by oncostatin M in combination with tumour necrosis factor α from bovine cartilage. Ann Rheum Dis 2003, 62:172-174.

51. El Mabrouk M, Qureshi HY, Li WQ, Sylvester J, Zafarullah M: Interleukin-4 antagonizes oncostatin M and transforming growth factor β-induced responses in articular chondrocytes. J Cell Biochem 2007, in press [epub ahead of print, June 1].

52. Sanders N, Firestein GS: Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin North Am 2001, 27:355-371.

53. Nagase H, Kashwagi M: Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003, 5:94-103.

54. Hui W, Li W, Kyesar G, Weber E, Klein MJ, Gravallese EM, Goldenring SR, Bromme D: Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritis synovium. Arthritis Rheum 2002, 46:663-674.

55. Salmen-Mankkonen HJ, Morko J, Vuona E: Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007, 8:315-323.

56. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ: Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: a mediator of systemic and local inflammation. Arthritis Rheum 2003, 48:3085-3095.

57. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T: Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005, 64:196-201.

58. Baeten D, Steenbakkers PG, Rijnders AM, Boots AM, Veale DJ: Detection of major histocompatibility complex human cartilage gp-39 complexes in rheumatoid arthritis synovium as a specific and independent histologic marker. Arthritis Rheum 2006, 54:481-487.

59. van Bilsen JH, van Dongen H, Lard LR, van der Voort EI, Elferink SB, Amin AR: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2005, 20:993-1002.
62. Recklies AD, Ling H, White C, Bernier SM: Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem 2005, 280:41213-41221.
63. Seki T, Masuko-Mongo K, Matsui T, Asahara H, Takigawa M, Nishimoto N, Kato T: Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis 2001, 60:49-54.
64. Knor T, Obemayr F, Bartnik E, Zien A, Aigner T: YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes. Ann Rheum Dis 2003, 62:995-998.
65. Saito S, Kondo S, Mishima S, Ishiguro N, Hasegawa Y, Sandell JI, Iwata H: Analysis of cartilage-derived retinoic-acid-sensi
tive protein 2B (CHI3L2) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis. J Bone Joint Surg Br 2002, 84:1066-1069.
66. Dayer JM: The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Arthritis Rheum 2001, 44:2697-2702.
67. van den Berg WB: Animal models of arthritis. What have we learned? J Rheumatol Suppl 2005, 72:7-9.
68. Horai R, Saijo S, Tanioka J, Nakae S, Sudo K, Okahara A, Ikuse T, Aida Y, Maeno M, Suzuki N, Namba A, Motohashi M, Matsumoto K, Varley AW, et al.: An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther 2004, 11:581-590.
69. Sack U, Sehm B, Kaltenberg F, Murr A, Lehmann J, Tannapfel A, Uberti K, Moessner A, Dietrich A, Emmrich F, et al.: Investigation of arthritic joint destruction by a novel fibrinolysis-based model. Ann NY Acad Sci 2005, 1051:291-298.
70. Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Cock IM, Cawston TE: The modulation of matrix metallopro
teinas and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002, 46:961-967.
71. Lubberts E, Koenders MI, Lubberts E, Koenders MI, van den Berg WB: The role of T cell interleukin-17 in inducing destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29-37.
72. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Berselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:850-869.
73. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Berselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Blocking of interleukin-17 during reactiva
tion of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005, 167:141-149.
74. Koenders MI, Joosten LA, van den Berg WB: Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006, 65(Suppl 3):iii29-iii33.
75. Koenders MI, Lubberts E, van der Loo FA, Oppers-Walgreen B, van den Berselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Interleukin-17 acts indepen
dently of TNF-α under articular conditions. J Immunol 2006, 176:6262-6269.
76. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, Kim HY: The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006, 54:2192-2193.
77. Morita D, Paulsen F, Mentlein R, Fay J, Kurz B, Schutz R, Wruk C, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Molen M, Takeda K, Akira S, Lubberts E, van der Loo FA, van den Berg WB: Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation. Critical role of myeloid differentiation factor 88. J Immunol 2003, 171:6145-6153.
78. Su SL, Tsai CD, Lee CH, Salter DM, Lee HS: Expression and regulation of Toll-like receptor 2 by IL-1β and fibronectin frag
defs in human articular chondrocytes. Osteoarthr Cartil 2005, 13:879-886.
79. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, Kim HY: Emerging cytokine targets in rheuma
toid arthritis. Curr Opin Rheumatol 2007, 19:246-251.
80. Koenders MI, Smeets RL, Koenders MI, van den Berselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Interleukin-18 promotes joint degeneration in osteo
arthritic chondrocytes. Clin Orthop Relat Res 2006, 447(Suppl 2):S27-S36.
81. Aida Y, Maeno M, Suzuki N, Namba A, Motohashi M, Matsumoto M, Makimura M, Matsumura H: The effect of IL-1β on the expression of inflammatory cytokines and their receptors in human chondrocytes. Life Sci 2006, 79:764-771.
82. Connell L, McInnes IB: New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2006, 20:865-878.
83. Connell L, McInnes IB, Shingleton WD, Degnan BA, Heath JK, Ver
nallis AB, Spaul J, Life PF, Hudson K, Cawston TE: Synergic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 2001, 44:1620-1632.
84. Choy E: Clinical experience with inhibition of interleukin-6. Rheum Dis Clin North Am 2004, 30:405-415.
85. Nishimoto N, Kishimoto T: Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006, 2:619-626.
86. van der Loo FA, de Hooge AS, Smeets RL, Bakker AC, Bennink MB, Amtz OJ, Joosten LA, van Beuningen HM, van de Kraan PK, Table of Contents Arthritis Research & Therapy Vol 9 No 5 Otero and goldring
inflammation and induces interleukin-1-driven cartilage destruction. Am J Pathol 2004, 165:959-967.

100. Matsui K, Tsutsumi H, Nakanishi K: Pathophysiological roles for IL-1β in inflammatory arthritis. Expert Opin Ther Targets 2003, 7:701-724.

101. Dai SM, Zhang J, Sha D, Zhang C, Xu J, Wang Y, Liu Y, Zhang X, Li X, Wang Y: Agonistic anti-IL-1β antibodies induce apoptosis in human synovial fibroblasts of rheumatoid arthritis. Arthritis Res Ther 2006, 8:R80.

102. John T, Kohl B, Mobasheri A, Ertel W, Shakibaei M: Interleukin-1α: the role of a pleiotropic cytokine in the pathogenesis of osteoarthritis. Cartilage 2007, 8:486-500.

103. Chon M, Kang HG, Cho SY, Lee DH, Lee HJ, Cho BS: Expression of interleukin-1 receptor antagonist by synovial fibroblasts and articular chondrocytes. Histol Histopathol 2007, 22:469-482.

104. Magne D, Palmer G, Bartol A, Meinerz B, Ates C: Tumor necrosis factor-α induction of matrix metalloproteinase-13: role for IL-1β and nitric oxide. Arthritis Res Ther 2007, 9:R40.

105. van de Loo FA, Smeets RL, van den Berg WB: Perforin: a new therapeutic target in rheumatoid arthritis. Bone Spine 2007, 84:1-3.

106. van de Loo FA, Geurts J, van den Berg WB: Perforin: a new therapeutic target in rheumatoid arthritis. Bone Spine 2007, 84:1-3.

107. van de Loo FA, Geurts J, van den Berg WB: Perforin: a new therapeutic target in rheumatoid arthritis. Bone Spine 2007, 84:1-3.

108. Neumann E, Judex M, Kullmann F, Grifka J, Robbins PD, Pap T, Gonzalez-Rey E, Chorny A, Varela N, O’Valle F, Delgado M: The new IL-1 receptor antagonist (IL-1Ra) pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum 2006, 54:1233-1245.

109. Dayer JM, Chicheportiche R, Juge-Aubry C, Meier C: Adipose tissue has anti-inflammatory properties: focus on IL-1 receptor antagonist (IL-1Ra). Ann N Y Acad Sci 2006, 1069:444-453.

110. J Rheumatol 2005, 42:2205-2206.

111. Masuko-Hongo K, Berenbaum F, Humbert L, Salvat C, Goldring MB, Thirion S: Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways. Arthritis Rheum 2004, 50:2829-2838.

112. Whitman M, Spencer JP, Zhu YZ, Armstrong JS, Schantz JT: Peroxynitrite-modified collagen-IL1 induces p38/ERK and NF-κB-dependent synthesis of prostaglandin E2 and nitric oxide in chondrocytically transduced mesenchymal progenitor cells. Osteoarthritis Cartilage 2006, 14:460-470.

113. Li X, Afif H, Cheng S, Martel-Pelletier J, Pelletier JP, Ranger P, Fahmi H: Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage chondrocytes. J Cell Biochem 2005, 92:887-895.

114. Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajotta K, Lavigne M, Fahmi H: Activation of piroximes promoter-activator receptor γ inhibits interleukin-1β-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts of patients interfering with Egf-1. J Biol Chem 2004, 279:22057-22065.

115. Francois M, Richette P, Tzagris L, Fitting C, Lemay C, Benallac M, Tahiri K, Corvol M: Activation of the piroxime promoter-activator-receptor pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum 2006, 54:1233-1245.

116. Otero M, Lag R, Gomez R, Dieguez C, Lago F, Gomez-Reino J, Guallio O: Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006, 45:944-950.

117. Dumond H, Presle N, Terlais B, Mainard D, Loeuille D, Netter P, Pottie P: Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003, 48:3118-3129.

118. Otero M, Lag R, Dietze JF, Reino JJ, Guallio O: Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Res Ther 2005, 7:R581-R591.

119. Palmer G, Aurnand-Lions M, Contassot E, Talabot-Ayer D, Ducastel-Gay D, Vesin J, Campagne V, Basset E, Cabuy C: Indirect effects of leptin receptor deficiency on lymphocyte populations and immune response in db/db mice. J Immunol 2006, 177:2899-2907.

120. Lago F, Dieguez C, Gomez-Reino JJ, Guallio O: The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007, 18:313-325.

121. Smeets RL, Vanbeersum S, Amtz OJ, Bennink MB, Joosten LA, van den Berg WB, van de Loo FA: A novel role for suppressor of cytokine signaling 3 in cartilage destruction via induction of chondrocyte desensitization toward insulin-like growth factor. Arthritis Rheum 2006, 54:1518-1528.

122. Yammani RR, Carlson CS, Bresnick AR, Loeser RF: Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum 2006, 54:2901-2911.

123. Baur S, Jendro MC, Wadde A, Kleber S, Stener F, Dinser N, Reif A, Faccin E, Godde S, Dinges H, et al.: Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006, 8:R171.

124. Milner JM, Kevorkian L, Young DA, Jones D, Wait R, Donell ST, Barksby E, Patterson AM, Middleton J, Gravatt BF, et al.: Fibroblast activation protein α is expressed by chondrocytes following a pro-inflamatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther 2006, 8:R23.

125. Firestein GS: NF-κB: Holy Grail for rheumatoid arthritis? Arthritis Rheum 2004, 50:2381-2386.

126. Vinci M, Brinkhoff CE: Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of...
complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002, 4:157-164.

157. Koch AE: Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005, 52:710-721.

158. Vergunst CE, van de Sande MG, Lebre MC, Tak PP: The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2005, 34:415-426.

159. Nakamura H, Masuko K, Yudoh K, Kato T, Nishioka K: Effects of cecocib on human chondrocytes – enhanced production of chemokines. Clin Exp Rheumatol 2007, 25:11-16.

160. Langford RM, Mazzetti I, Marcu KB, Facchini A: Chemokines in cartilage degradation. Clin Orthop Relat Res 2004, 427(Suppl): SS3-S61.

161. Iwamoto T, Okamoto H, Ikuni N, Takeuchi M, Toyama Y, Tomatsu T, Kamatani N, Momohara S: Monocyte chemoattractant protein-1 (MCP-1/CCL2) is highly expressed in cartilage from patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:421-424.

162. Kanbe T, Takemura T, Takeuchi K, Chen Q, Takagiishi K, Inoue K: Synovectomy reduces stromal-cell-derived factor-1 (SDF-1) which is involved in the destruction of cartilage in osteoarthritis and rheumatoid arthritis. J Bone Joint Surg Br 2004, 86: 296-300.

163. Green DM, Noble PC, Ahuero JS, Birdsal HH: Cellular events leading to chondrocyte death after cartilage impact injury. Arthritis Res 2006, 8:5108-1517.

164. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, Veale DJ: Angiopoietins, growth factors, and vascular morpholgy in early arthritis. J Rheumatol 2003, 30:260-268.

165. Szekanecz Z, Gaspar L, Koch AE: Angiogenesis in rheumatoid arthritis. Front Biosci 2004, 9:17681-1785.

166. Honarati MC, Neri S, Cattini L, Facchini A: Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2005, 13:345-352.

167. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, Fitzgerald O, Bresnihan B, Veale DJ: Osteoclast M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 2006, 54:3152-3162.

168. Del Carlo M, Schwartz D, Erickson EA, Loeser RF: Endogenous production of reactive oxygen species is required for stimulation of human articular chondrocyte matrix metalloproteinase production by fibroblast fragments. Free Radic Biol Med 2007, 42:1350-1358.

169. Xu J, Peng H, Wu D, Hu K, Goldring MB, Olsen BR, Li Y: Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with osteoarthritis in mice. J Biol Chem 2005, 280:548-555.

170. Hu K, Xu L, Cao L, Flahiff CM, Brussiau J, Ho K, Setton LA, Youn J, Guiila F, Olsen BR, et al.: Pathogenesis of osteoarthritis-like changes in the joints of mice deficient in type IX collagen. Arthritis Rheum 2006, 54:2891-2900.

171. Knudsen CB, Knudsen W: Hylauronan and CD44: modulators of chondrocyte metabolism. Clin Orthop Relat Res 2004, 427 (Suppl):S152-S182.

172. Takagi T, Okamoto R, Suzuki K, Hayashi T, Sato M, Kurosaka N, Koshino T: Up-regulation of CD44 in rheumatoid chondrocytes. Scand J Rheumatol 2001, 30:110-113.

173. Naor D, Nedvetski S: CD44 in rheumatoid arthritis. Arthritis Res Ther 2003, 5:R105-110.

174. Ohno S, Im HJ, Knudsen CB, Knudsen W: Hylauronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFкB and p38 MAP kinase in articular chondrocytes. J Biol Chem 2006, 281:17589-17596.

175. Takagi T, Okamoto R, Suzuki K, Hayashi T, Sato M, Kurosaka N, Koshino T: Up-regulation of CD44 in rheumatoid chondrocytes. Scand J Rheumatol 2001, 30:110-113.

176. Visintin I: Cell junctions and tissue remodelling. EMBO J 1999, 18:2049-2059.

177. Valencia X, Higgins JM, Kiener HP, Lee DM, Podrebarac TA, Dascher CC, Watts GF, Miozguchi E, Simmons B, Patel DD, et al.: Caderin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med 2004, 200:1673-1679.

178. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al.: Role of cytokines and chemokines in cartilage and bone destruction in arthritis. Curr Opin Orthopedics 2002, 13:351-362.
Takeichi M, Brenner MB: Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007, 315:1006-1010.

Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.

Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M: The osteoprotegerin/receptor activator of nuclear factor κκB/receptor activator of nuclear factor κκB ligand system in cartilage. Arthritis Rheum 2001, 44:2768-2776.

Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallesse EM: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.

Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, Schett G: Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006, 54:463-472.

Day TF, Guo X, Garrett-Beal L, Yang Y: Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739-750.

Tamamura Y, Otani T, Kanatani N, Koyama E, Kitagaki J, Komori T, Yamada Y, Costantini F, Wakisaka S, Pacifici M, et al.: Developmental regulation of Wnt/β-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem 2005, 280:19185-19195.

Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, et al.: Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.

Goldring SR, Goldring MB: Eating bone or adding it: the Wnt pathway decides. Nat Med 2007, 13:133-134.